Krakow, Poland – 30 May 2018 – Selvita is participating and presenting at the 4th Annual Immuno-Oncology BD&L and Investment Forum, taking place on June 1st, 2018, in Chicago, USA during the first day of American Society of Clinical Oncology (ASCO). The presentation will be held by Dr. Krzysztof Brzozka, Chief…
Selvita shows strong business growth in Q1 2018
Krakow, Poland – 25 May 2018 – Selvita, one of the largest drug discovery companies in Europe, has recently published quarterly financial results demonstrating its continued dynamic business growth. Revenues from the Services Segment in Q1 2018 totaled PLN 13.6 MM, which represents growth of 53% in comparison to the…
Selvita and Sandoz chemists published in Bioorganic & Medicinal Chemistry
Krakow, Poland – 08 May 2018 – Selvita and Sandoz researchers have recently jointly published an article: “A short synthesis of Dronedarone”, which appeared in the Bioorganic & Medicinal Chemistry. The publication presents a modification of the Nenitzescu reaction was used to obtain Dronedarone from quinonimine 20 and 1,3-diketone 14…
Institute of Hematology and Transfusion Medicine and Selvita publish joint research results on SEL24 potential in Chronic Lymphocytic Leukemia
Krakow, Poland – 26 April 2018 – Institute of Hematology and Transfusion Medicine, the leading Polish hematology and blood transfusion institute, jointly with Selvita, a clinical stage drug discovery and development company focused on innovative medicines for oncology patients, have published results of a research projects concerning therapeutic potential of…
Selvita participates in BioTrinity 2018
Kraków, Poland – 23 April 2018 – Selvita will participate in the 2018 edition of BioTrinity conference, taking place in London, UK, on April 23 – 25, 2018. BioTrinity is one of Europe’s leading biopartnering and investment conferences, and the largest of its type in the UK. The conference offers…
Selvita publishes research results on SEL24 in Oncotarget
Krakow, Poland – 16 April 2018 – Selvita, a clinical stage drug discovery and development company focused on innovative medicines for oncology patients, has published recent results of a research concerning therapeutic potential of SEL24 in Acute Myeloid Leukemia (AML). The article titled “A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits…